Enhanced cytogenetic and antitumor effects by 9-nitrocamptothecin and antineoplastics

Teratogenesis Carcinogenesis and Mutagenesis

Volumn 20, Issue 3, 2000, Pages 141-146

  Karaberis, E ^a   Mourelatos, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

9 nitro 20(S) camptothecin; Antineoplastic activity; Cell kinetics; Epirubicin; Melphalan; SCE

Indexed keywords

EPIRUBICIN; MELPHALAN; RUBITECAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CELL KINETICS; CELL PROLIFERATION; CONTROLLED STUDY; CYTOGENETICS; DRUG POTENTIATION; LEUKEMIA CELL; LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SISTER CHROMATID EXCHANGE;

ANIMALIA;

EID: 0034080854     PISSN: 02703211     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1520-6866(2000)20:3<141::AID-TCM5>3.0.CO;2-D     Document Type: Article

References (13)

1. Pantazis P, Kozielski A, Mendoza J, Early J, Hinz H, Giovanella C. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. In J Cancer 1993;53:863-871.
2. Mourelatos D. Chromosomes study as predictor of chemoresponse of tumours. Cancer J 1996;9:136-141.
3. Papageorgiou A, Nikolaropoulos S, Arsenou E, Karaberis E, Mourelatos D. Enhanced cytogenetic and antineoplastic effects by the combined action of two esteric steroidal derivatives of nitrogen mustards. Chemotherapy 1999;45:61-67.
4. Goto K, Maeda S, Kano Y, Sugiyama T. Factors involved in differential Giemsa staining of sister chromatids. Chromosoma 1978;66:351-359.
5. Goldin A, Sofina Z, Syrkin A. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. Natl Cancer Inst Monogr 1980;55:35-36.
6. Wood RD. DNA repair in eukaryotes. Annu Rev Biochem 1996;65:135-167.
7. Hanawalt P. Genomic instability: Environmental invasion and the enemies within. Mutat Res 1998;400:117-125.
8. Backer LC. Genotoxicity of inhibitors of DNA topoisomerase 1 (cainptothecin) and 2 (m-AMSA) in vivo and in vitro. Mutagenesis 1990;5:541-547.
9. Verchraegen C, Natelson E, Giovanella B, Kavanagh J, Kudelka A, Freedman R, Edwards C. A phase I clinical and pharmacological study of oral 9-nitro-camptothecin, a novel water-insoluble topoisomerase I inhibitor. Anticancer Drugs 1998;9:36-44.
10. Tofilon P, Basic I, Milas L. Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro SCE assay. Cancer Res 1985;45:2025-2030.
11. Mourelatos D, Dozi J, Kotsis A, Gourtsas C. Enhancement of cytogenetic damage and of antineoplastic effect by caffeine in Ehrlich ascites tumour cells treated with cyclophosphamide in vivo. Cancer Res 1988;48:1129-1131.
12. Deen DF, Kendall LA, Marton LJ, Tofilon P. Prediction of human tumor cell chemosensitivity using the SCE assay. Cancer Res 1986;46:1599-1602.
13. Morris S, Heflich R. A comparison of the toxic and SCE-inducing effects of inhibitors of ADP-ribosyltransferase in CHO-cells. Mutat Res 1984;126:63-71.